This move is archived. Current quotes and coverage live on the stock page.
Follow EPRX
Eupraxia Pharmaceuticals Inc faces a challenging trading day, with its stock price falling by over 2%.
Eupraxia Pharmaceuticals Inc (EPRX.TO) is experiencing a downturn on the TSX, closing down 2.09% at CA$8.90. This decline raises questions about investor sentiment and the company's recent performance amid a lack of significant news.
Investor takeaway: Investors should closely monitor Eupraxia's stock movements, particularly given the absence of recent positive developments that could support its valuation.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$633.64M
52W high
$13.08
52W low
$7.35
1W change
-15.14%
Beta
1.22
Analyst Price Targets
Based on analyst covering EPRX · as of Sep 28, 2026
Wall Street analysts forecast EPRX stock price to rise 74.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+74.5% Upside
Previously C$16.00 on Sep 17, 2026
Current Price
C$9.36
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
95.3%
Annualized
90-Day Vol
70.0%
Annualized
Trend (90d)
+4.1%
Annualized drift
90d Mean
C$9.50
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.41 | C$6.77 – C$13.07 |
| 60 trading days | C$9.45 | C$5.94 – C$15.04 |
| 90 trading days | C$9.50 | C$5.37 – C$16.78 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Eupraxia Pharmaceuticals Inc down 2.09% today
The stock's decline reflects broader market concerns and investor hesitation, especially in the absence of recent positive catalysts.
Bull case
Eupraxia has shown promise in its clinical trials, especially with the EP-104GI program. If this program succeeds, it could lead to significant growth for the company.
Bear case
The current lack of news and the stock's recent performance may suggest that investor confidence is fading, making it a risky option in the short term.
Advertisement
Market Reaction
Eupraxia's stock performance today mirrors a general caution among investors, particularly due to the absence of any recent announcements or financial results that might have boosted confidence. The 2.09% drop could indicate a careful approach from the market as investors assess the company’s future prospects.
What Lies Ahead for Eupraxia?
Without new developments to support its stock price, Eupraxia Pharmaceuticals Inc faces an uphill battle to regain investor trust. The company's recent financial results and clinical milestones are encouraging, but without immediate catalysts, the stock may continue to struggle. Investors should keep an eye on upcoming announcements that could influence market sentiment.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
